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Abstract
In this paper, we present the dfcomb R package for the implementation of a single
prospective clinical trial or simulation studies of phase I combination trials in oncology.
The aim is to present the features of the package and to illustrate how to use it in
practice though dierent examples. The use of combination clinical trials is growing,
but the implementation of existing model-based methods is complex, so this package
should promote the use of innovative adaptive designs for early phases combination
trials.
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1 Introduction
Most phase I cytotoxic dose-nding studies seek to establish a dose high enough to be able
to observe potential ecacy while maintaining the toxicity rate within certain pre-dened
acceptable limits. Phase I studies in oncology focus on determining the maximum tolerated
dose (MTD) that will be used in further experiments [1, 2, 3]. However, nowadays, it is rare
to nd new agents that perform much better than existing therapeutic strategies. When
combining two or more agents, there may be a synergistic eect in terms of ecacy. That
is why investigators wish to increase overall anti-tumor action and survival by combining
several agents: cytotoxics or targeted molecules or both. As a result, it is dicult to suppose
that each agent will act independently in terms of toxicity.
When combining two agents, either a cytotoxic with a cytotoxic or a cytotoxic with a
molecularly targeted agent (MTA), the underlying modeling assumptions diverge. Indeed,
these two types of combinations dier in the shape of the dose-ecacy curves. For cytotoxic
agents, a higher dose yields a greater response, but also leads to higher toxicity. However,
the dose-ecacy relationship of the MTA may not follow the same monotonic pattern. The
ecacy of some MTAs often increases at low dose levels and then plateaus (or approximately
plateaus) at higher dose levels once a saturation level has been reached [4, 5, 6, 7]. Recently,
we proposed two novel statistical designs for each combination type [8, 9]. In practice, these
methods are based on Bayesian approaches that require high statistical and programming
skills.
Many of the newly developed statistical methods for combination designs do not include
software for their implementation. Some exceptions include POCRM [10] and PIPE [11]. As
a result, many combination studies are still conducted with methods used for single agents
[12].
In this article, we present a new R [13] package dfcomb, which provides functions for
the conduct of a prospective single trial and simulation studies of the combination of two
cytotoxics or a cytotoxic and an MTA in phase I dose-nding trials [8, 9]. The primary
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features of dfcomb are as follows:
 Generates simulation replicates of phase I/II clinical trials for combination studies of
two cytotoxic agents or a cytotoxic with an MTA.
 Determines the next or recommended combination in a phase I/II combination clinical
trial.
The primary objective of this paper is to present the features of each method and to
describe how to use the R dfcomb package in practice. Section 2 describes the models and
computational methods of the package. Section 3 presents the R functions with simulations
and examples of two dataset clinical trials, and in section 4 we conclude with a discussion.
2 Computational methods
2.1 Combination of two agents where toxicity and ecacy increase
with both agents (CombIncrease_sim and CombIncrease_next)
Riviere et al [8] proposed a Bayesian phase I dose-nding design for clinical trials combining
two agents where the toxicity of both agents is assumed to increase with dose levels. As in
classic phase I design, the design only accounted for toxicity because the ecacy was assumed
to be correlated with toxicity and to increase with dose levels. Therefore, the aim was to
determine the maximum tolerated dose (MTD) in the context of the two-drug combination,
dened as the combination associated with a toxicity closest to a maximum pre-dened dose-
limiting toxicity (DLT) rate.
The combination toxicity probability at dose (j; k), j;k, composed of dose level j of agent
1 (j = 1; : : : ; J) and dose level k of agent 2 (k = 1; : : : ; K), was modeled using a 4-parameter
logistic model:
logit(j;k) = 0 + 1uj + 2vk + 3ujvk;
3
where uj and vk denote the standardized doses of agents 1 and 2, 0, 1, 2 and 3 are
unknown parameters such that 1 > 0, 2 > 0, 8k; 1 + 3vk > 0 and 8j; 2 + 3uj > 0,
ensuring that the toxicity probability increases with the dose levels of both agents, and
intercept 0 2 R. Gibbs sampling was used to sample in posterior distributions and estimate
all posterior probabilities and parameters.
During the trial, determination of dose escalation and de-escalation to adjacent combi-
nations was based on the uncertainty in P (j;k < jdata), that is on the probability that
the current combination is safe enough. At the end of the trial, the MTD was selected as
the tested combination with highest posterior probability, P (j;k 2 [   ;  + ]), of being
in a pre-dened interval around the targeted toxicity . We implemented an algorithm-based
start-up phase to gather enough information at the beginning of the trial in order to have
reliable estimates of posterior probabilities. Moreover, we added stopping rules in cases
where all dose levels were too toxic or all dose levels were far from the targeted toxicity (and
therefore potentially ineective). The details of the method can be found in [8].
2.2 Combination of two agents where the ecacy of one of the
agents can plateau (CombPlateau_sim and CombPlateau_next)
Riviere et al [9] proposed a Bayesian phase I/II dose-nding design for clinical trials combining
two agents where the toxicity and ecacy of both agents are assumed to increase with dose
levels, but the ecacy of one agent can plateau (e.g. molecularly targeted agent).
The toxicity is assumed to be a binary outcome (1 if DLT, 0 otherwise), and the toxicity
probability at combination (j; k) was modeled using a logistic model:
logit(pjk) = 0 + 1uj + 2vk
where and uj and vk are standardized doses ascribed to the jth dose level of agent 1 and
the kth dose level of agent 2, 0, 1, and 2 are unknown parameters such that 1 > 0 and
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2 > 0, so that toxicity monotonically increases with the dose levels of both agents 1 and 2.
In contrast, the ecacy response may require a longer follow-up time to be scored and was
therefore considered as a time-to-event outcome. When combining an MTA with a cytotoxic
agent, ecacy is expected to increase monotonically with the dose of the cytotoxic agent,
but initially increases and then plateaus with the dose of the MTA, after the MTA reaches
a level of saturation. We modeled the time to ecacy for the combination (j; k) using a
proportional hazard model, jk(t), augmented with a plateau parameter  :
jk(t) = 0(t)expf1wj + 2(zk1(k < ) + z1(k  ))g;
where 0(t) is the baseline hazard, 1(:) denotes the indicator function, and wj and zk are
standardized doses. We assume that 1 > 0 and 2 > 0, and therefore ecacy increases
monotonically with the dose of the cytotoxic agent 1. The plateau parameter  is an integer
between 1 and K and indicates at which dose level of agent 2 ecacy reaches a plateau. We
assume an exponential distribution for the time to ecacy with a constant baseline hazard,
i.e., 0(t) = 0, resulting in the following survival function for the time to ecacy:
Sjk(t) = exp[ 0t expf1wj + 2(zk1(k < ) + z1(k  ))g]:
Then, the response rate, qjk, at the end of the full follow-up time T for patients treated at
the combination (j; k), is given by qjk = 1  Sjk(T ).
Gibbs sampling was used to sample in toxicity and ecacy posterior distributions and
to estimate all posterior probabilities and parameters. The next optimal combination to
be administered was selected as the admissible (safe: P (pjk > ) < CT, and eective:
P (Sjk(T ) > )  CE; where CT and CE are probability thresholds that need to be calibrated
through a simulation study) combination with the highest estimate of ecacy, along with
the lowest estimate of toxicity (if plateau reached).
We implemented an algorithm-based start-up phase to gather enough information at the
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beginning of the trial in order to have reliable estimates of posterior probabilities. If during
the trial, all combinations were inadmissible, the trial was stopped without a recommendation
of combination. The details of the method can be found in [9]
3 R-functions
In this section, for each of the two methods described above, we present code examples and
the corresponding outputs for: (1) simulation replicates of clinical trials, and (2) application
to data of an ongoing clinical trial.
3.1 Combination of two agents where toxicity and ecacy increase
with both agents (CombIncrease_sim and CombIncrease_next)
3.1.1 Simulation
We will illustrate the features of the CombIncrease_sim function. We considered 5 dose
levels for the rst agent (ndose_a1=5) and 3 dose levels for the second agent (ndose_a2=3).
Then we dened our scenario representing the true toxicity probabilities of the combination.
True toxicity probabilities should be entered in a matrix with agent 1 in rows and agent 2
in columns, with increasing toxicity probabilities with both row and column numbers, as for
example:
p_tox <- matrix(c(0.05,0.10,0.15,0.30,0.45,
0.10,0.15,0.30,0.45,0.55,
0.15,0.30,0.45,0.50,0.60),nrow=5,ncol=3)
We chose a targeted toxicity probability (target) of 0:30, which is common in oncology
due to the aggressiveness of the disease, and a targeted interval ([target_min;target_max])
of [0:20; 0:40]. We then provided initial guesses for toxicity probabilities for the dose levels
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of agent 1, and agent 2. Typically, if information from phase I clinical trials for these agents
individually is available, it can be incorporated to set up the prior toxicity probabilities.
prior_tox_a1 <- c(0.12, 0.2, 0.3, 0.4, 0.5)
prior_tox_a2 <- c(0.2, 0.3, 0.4)
In this example, if there is no early termination of the trial, a maximum total number
of 20 cohorts (n_cohort) of 3 patients (cohort) should be included (that is 60 patients).
The toxicity outcome was binary (tite=FALSE), 1 if a DLT is observed, 0 otherwise. We
performed 2000 replicates of phase I clinical trials (nsim).
In order to determine the combination of drugs for the next cohort of patients, probability
thresholds ce and cd have to be dened. They are critical for the performance of the design
as they control the dose escalation and de-escalation. When setting up a new clinical trial,
the values of ce and cd should be carefully calibrated through simulation, to ensure good
operating characteristics of the design. In practice, this can be performed as follows. First,
dene a set of representative dose{toxicity scenarios that may be encountered in the trial,
and then perform simulations using dierent values of ce and cd to evaluate the performance
of the design. This is a trial-and-error process and may involve repeatedly tuning the values
of ce and cd based on the simulation results. The goal is to nd the values of ce and cd
that yield good overall performance across dierent scenarios (e.g., the percentage of correct
selection of the MTD, the number of patients exposed to over-toxic combinations or under-
toxic combinations). We xed these settings to default values, which seems to give good
performance in a large variety of scenarios [8].
Finally, investigators may wish to stop a trial early when all combinations are estimated
to be unacceptable in terms of toxicity. Therefore, we propose a stopping rule when the lowest
combination is too toxic. In our example, to stop the trial early at least 6 patients should
have been included in the lowest combination (n_min) and the probability that the estimated
toxicity probability at that combination is above the target (0:30) should be greater than 0:95,
meaning that the probability of over-dosing is high. Again, for a simpler use, these arguments
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were set by default to values giving, in general, good performances for inexperienced users.
Then users can choose to calibrate them by simulation studies.
This results in the following call to the function:
sim <- CombIncrease_sim(ndose_a1=5, ndose_a2=3, p_tox=p_tox, target=0.30,
target_min=0.20, target_max=0.40, prior_tox_a1=prior_tox_a1,
prior_tox_a2=prior_tox_a2, n_cohort=20, cohort=3, tite=FALSE, nsim=2000,
c_e=0.85, c_d=0.45, c_stop=0.95, n_min=6, seed = 14061991)
A progress bar appears that indicates the progress of the number of simulations chosen.
The simulation can be long, and it is normal to wait some time before the bar changes.
Calculation time will clearly depend on the computer resources the user has at his or her dis-
posal, but this example takes about 3 hours 45 minutes to run on a single portable computer
with an Intel Core i7. If the call to the function is stopped before its end, the results for the
current number of simulations ended are displayed. The generated output is as follows:
True toxicities:
Agent 1
Agent 2 1 2 3 4 5
3 0.15 0.30 0.45 0.50 0.60
2 0.10 0.15 0.30 0.45 0.55
1 0.05 0.10 0.15 0.30 0.45
True toxicity probabilities entered are recalled, and then the results show at each com-
bination (1) the percentage of selection, (2) the mean number of patients included, and (3)
the mean number of observed toxicities. Therefore, the percentage of correct selection of a
true MTD (combination associated with the toxicity target of 30%) is 28:30+40:65+6:90 =
75:85%. The mean number of patients and toxicities of each combination can be used to
evaluate the number of patients exposed to over-dosing or under-dosing.
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Percentage of Selection:
Agent 1
Agent 2 1 2 3 4 5
3 6.0 28.30 6.40 0.15 0.00
2 0.2 4.45 40.65 3.75 0.05
1 0.0 0.05 3.05 6.90 0.05
Number of patients:
Agent 1
Agent 2 1 2 3 4 5
3 4.24 9.83 5.59 0.78 0.09
2 0.96 9.28 13.44 2.10 0.07
1 3.81 1.17 5.48 2.98 0.19
Number of toxicities:
Agent 1
Agent 2 1 2 3 4 5
3 0.61 2.93 2.57 0.40 0.06
2 0.09 1.42 4.05 0.95 0.04
1 0.19 0.12 0.80 0.93 0.09
The trials did not stop early and included the total sample size of 60 patients. Other
entries are also recalled as follows:
Percentage of inconclusive trials: 0
The minimum number of cohorts to stop the trial is: 2
Number of simulations: 2000
Cohort size: 3
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Number of cohort planned: 20
Total patients accrued: 60
Toxicity target: 0.3
Targeted toxicity interval: [ 0.2 , 0.4 ]
Prior toxicity probabilities for agent 1:
[1] 0.12 0.20 0.30 0.40 0.50
Prior toxicity probabilities for agent 2:
[1] 0.2 0.3 0.4
Escalation threshold: 0.85
Deescalation threshold: 0.45
Stopping threshold: 0.95
Toxicity is not a time-to-event but binary
3.1.2 Application
In a real clinical trial, the CombIncrease_next function determines the next combination to
administer. As with CombIncrease_sim, the number of dose levels for each agent, targeted
toxicities, initial guesses for toxicity probabilities, and minimum number of patients for early
termination should be specied.
prior_tox_a1 <- c(0.12, 0.2, 0.3, 0.4, 0.5)
prior_tox_a2 <- c(0.2, 0.3, 0.4)
In this example, we considered that the trial is still ongoing (final=FALSE), and cur-
rently 18 patients have been enrolled (pat_incl). For each of these 18 patients, two vectors
corresponding to the dose levels of each agent administered to the patient should be given,
as for example:
dose1 <- c(1,1,1,2,2,2,3,3,3,3,3,3,3,3,3,4,4,4)
dose2 <- c(1,1,1,2,2,2,3,3,3,2,2,2,1,1,1,1,1,1)
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In the following example, the last three patients have received dose 4 of agent 1 and dose
1 of agent 2. The toxicity outcome is binary (tite=FALSE), so the user have to input a
vector of toxicity containing for each patient: 1 if a dose-limiting toxicity is observed and 0
otherwise.
toxicity <- c(0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1)
If the toxicity is considered as a time-to-event (tite=TRUE), then two vectors containing
the time-to-toxicity and the follow-up time for each patient as well as the value corresponding
to the full follow-up time window should be given. The detailed example results in the
following call to the function:
next_dose <- CombIncrease_next(ndose_a1=5, ndose_a2=3, target=0.3,
target_min=0.20, target_max=0.40, prior_tox_a1=prior_tox_a1,
prior_tox_a2=prior_tox_a2, final=FALSE, pat_incl=18, dose_adm1=dose1,
dose_adm2=dose2, tite=FALSE, toxicity=toxicity, n_min=6)
Another possible option include in_startup (set at TRUE by default). If FALSE the
start-up phase is forced to be ended and thus estimation can be performed even if the clinical
trial did not follow the start-up phase recommended by the original design. This code takes
less than one second to run. The generated output is composed as the recalled number of
patients and toxicities at each combination:
Number of patients:
Agent 1
Agent 2 1 2 3 4 5
3 0 0 3 0 0
2 0 3 3 0 0
1 3 0 3 3 0
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Number of toxicities:
Agent 1
Agent 2 1 2 3 4 5
3 0 0 1 0 0
2 0 0 1 0 0
1 0 0 0 1 0
The estimated posterior probabilities for toxicity, under/over-dosing are reported. They
are used to evaluate the safety of combinations and lead to the recommendation of the next
most appropriate combination:
Toxicity prob:
Agent 1
Agent 2 1 2 3 4 5
3 0.10 0.21 0.39 0.57 0.70
2 0.03 0.06 0.18 0.42 0.65
1 0.01 0.02 0.07 0.25 0.58
P(toxicity prob < target):
Agent 1
Agent 2 1 2 3 4 5
3 0.95 0.77 0.32 0.10 0.05
2 1.00 0.99 0.87 0.28 0.08
1 1.00 1.00 0.99 0.68 0.17
Prob underdosing:
Agent 1
Agent 2 1 2 3 4 5
3 0.85 0.54 0.13 0.03 0.01
12
2 0.99 0.96 0.63 0.11 0.03
1 1.00 0.99 0.95 0.42 0.08
Prob targeted interval:
Agent 1
Agent 2 1 2 3 4 5
3 0.13 0.36 0.42 0.18 0.09
2 0.01 0.04 0.34 0.38 0.14
1 0.00 0.00 0.05 0.43 0.19
Prob overdosing:
Agent 1
Agent 2 1 2 3 4 5
3 0.02 0.1 0.45 0.78 0.90
2 0.00 0.0 0.03 0.51 0.83
1 0.00 0.0 0.00 0.15 0.73
The next recommended combination is (4; 1) (dose level 4 of agent 1, and dose level 1 of
agent 2). Entries as well as accumulated information are reported.
Start-up phase ended: YES
NEXT RECOMMENDED COMBINATION: (4,1)
Number of patients included: 18
Toxicity target: 0.3
Targeted toxicity interval: [ 0.2 , 0.4 ]
Prior toxicity probabilities for agent 1:
[1] 0.12 0.20 0.30 0.40 0.50
Prior toxicity probabilities for agent 2:
13
[1] 0.2 0.3 0.4
The minimum number of patients to stop the trial is: 6
Escalation threshold: 0.85
Deescalation threshold: 0.55
Stopping threshold: 0.95
Toxicity is not a time-to-event but binary
3.2 Combination of two agents where the ecacy of one of the
agents can plateau (CombPlateau_sim and CombPlateau_next)
3.2.1 Simulation
We will illustrate the features of the CombPlateau_sim function. We considered 3 dose
levels for the cytotoxic agent (ndose_a1) and 4 dose levels for the molecularly targeted agent
(ndose_a2). We dened the true toxicity and ecacy probabilities of the combination. They
should be entered in rows for the cytotoxic agent and in columns for the MTA, with increasing
toxicity/ecacy probabilities with both row and column numbers:
p_tox <- t(matrix(c(0.10,0.15,0.30,0.45,
0.15,0.30,0.45,0.50,
0.30,0.45,0.55,0.65),nrow=4,ncol=3))
p_eff <- t(matrix(c(0.25,0.25,0.26,0.27,
0.40,0.41,0.41,0.42,
0.55,0.55,0.56,0.56),nrow=4,ncol=3))
We chose a maximum targeted toxicity probability of 0:30 (tox_max) and a minimum
ecacy probability of 0:20 (eff_min). We then provided initial guesses for toxicity/ecacy
probabilities for the dose levels of both agents:
prior_tox_a1 <- c(0.2, 0.3, 0.4)
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prior_eff_a1 <- c(0.3, 0.4, 0.5)
prior_tox_a2 <- c(0.12, 0.2, 0.3, 0.4)
prior_eff_a2 <- c(0.3, 0.4, 0.5, 0.59)
Again, if information from phase I clinical trials for these agents used as single-agents is
available, it can be incorporated to set up the prior toxicity probabilities. In this example,
if there is no early termination of the trial, a maximum sample size of 75 enrolled patients
is needed (n), with a cohort of 3 patients throughout the trial (cohort_start, cohort). As
ecacy is considered as a time-to-event outcome (time-to-progression), the full follow-up time
to assess ecacy should be specied (time_full). In this example we chose a follow-up time
of 7 weeks. The patient accrual is simulated using a Poisson process. We chose a rate of 0:28
(poisson_rate) meaning that on average 1 patient arrives every 3.5 weeks. Even if toxicity
should be quickly ascertainable, it is possible to consider that before dose determination the
cohort should be followed up for a minimum time to assess toxicity. Usually in oncology,
3 weeks are needed to evaluate toxicity. In the following example, we did not constrain a
minimum follow-up time before dose determination and set cycle to 0. We performed 2000
replicates of phase I/II clinical trials (nsim).
In order to determine the combination of drugs for the next cohort of patients, toxicity
and ecacy thresholds ctox and ceff have to be dened. These probabilities are used to dene
combinations that are admissible in terms of toxicity and ecacy. A smaller ctox will be more
stringent and require a safer combination in terms of toxicity, and a higher ceff will require a
more eective combination. When setting up a new clinical trial, the values of ctox and ceff
should be calibrated through simulation depending on the desired operating characteristics
of the design. The following call to the function was performed:
sim <- CombPlateau_sim(ndose_a1=3, ndose_a2=4, p_tox=p_tox, p_eff=p_eff,
tox_max=0.30, eff_min=0.20, prior_tox_a1=prior_tox_a1,
prior_tox_a2=prior_tox_a2, prior_eff_a1=prior_eff_a1,
prior_eff_a2=prior_eff_a2, n=75, cohort_start=3, cohort=3, time_full=7,
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poisson_rate=0.28, cycle=0, nsim=2000, c_tox=0.85, c_eff=0.10,
seed = 2174892, threads=0)
The seed for simulations can be chosen. Finally, as these simulations are computationally
intensive, the run time can be long. The argument threads is used to specify the number
of threads of the computer to use; by default 0 uses all threads. As this design deals with
both toxicity and ecacy, simulations in general take longer to execute than for the previous
design. We run this code in a little over 2 days (52 hours).
The generated output is rst composed of the recalled toxicity and ecacy probabilities:
True toxicities:
Agent 1
Agent 2 1 2 3
4 0.45 0.50 0.65
3 0.30 0.45 0.55
2 0.15 0.30 0.45
1 0.10 0.15 0.30
True efficacies:
Agent 1
Agent 2 1 2 3
4 0.27 0.42 0.56
3 0.26 0.41 0.56
2 0.25 0.41 0.55
1 0.25 0.40 0.55
Percentage of Selection:
Agent 1
Agent 2 1 2 3
16
4 0.35 0.2 0.00
3 1.05 0.4 0.20
2 0.50 7.0 5.55
1 0.05 8.5 73.25
Number of patients:
Agent 1
Agent 2 1 2 3
4 1.92 0.26 0.29
3 3.71 1.27 1.29
2 4.00 5.45 8.65
1 3.88 7.07 35.13
Number of toxicities:
Agent 1
Agent 2 1 2 3
4 0.85 0.12 0.19
3 1.11 0.58 0.71
2 0.61 1.64 3.90
1 0.41 1.04 10.51
Number of efficacies:
Agent 1
Agent 2 1 2 3
4 0.50 0.11 0.16
3 0.95 0.53 0.71
2 1.02 2.25 4.80
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1 0.98 2.83 19.28
Percentage of inconclusive trials: 2.95
The results show that the percentage of correct selection of the optimal combination
(3; 1) is 73:25%. The trial was stopped at 2.95% because no combination was found that was
acceptable in terms of both toxicity and ecacy.
Number of simulations: 2000
Cohort size for the start-up phase: 3
Cohort size for the model-based phase: 3
Total sample size: 75
Total patients accrued: 72.9
Toxicity upper bound: 0.3
Efficacy lower bound: 0.2
Prior toxicity probabilities for agent 1:
[1] 0.2 0.3 0.4
Prior toxicity probabilities for agent 2:
[1] 0.12 0.20 0.30 0.40
Prior efficacy probabilities for agent 1:
[1] 0.3 0.4 0.5
Prior efficacy probabilities for agent 2:
[1] 0.30 0.40 0.50 0.59
Toxicity threshold: 0.85
Efficacy threshold: 0.1
Toxicity is binary
Efficacy is a time-to-event
Full follow-up time: 7
Minimum waiting time between two dose cohorts is of one toxicity cycle of: 0
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Patient arrival is modeled as a Poisson process with rate: 0.28
Trial mean duration: 268.3669
The mean trial duration was 268 weeks, that is about 5 years, if only one center is
recruiting, with on average one patient enrolled every 3.5 weeks. Entries and accumulated
data are reported.
3.2.2 Application
When used for a real clinical trial, the CombPlateau_next function determines the next com-
bination to administer. As with CombPlateau_sim, the number of dose levels for each agent,
maximum toxicity, minimum ecacy, and initial guesses for toxicity/ecacy probabilities
should be specied:
prior_tox_a1 <- c(0.2, 0.3, 0.4)
prior_eff_a1 <- c(0.3, 0.4, 0.5)
prior_tox_a2 <- c(0.12, 0.2, 0.3, 0.4)
prior_eff_a2 <- c(0.3, 0.4, 0.5, 0.59)
stage is an integer with value 0 if less than half of the total sample size has been included,
1 if more than half of the total sample size has been included but the trial is still ongoing,
and 2 if the trial is over and the dose recommendation should be made. We considered that
the trial is ongoing with less than half of the total sample size included, setting stage to 0,
and the start-up phase is nished (in_startup=FALSE). After the start-up phase, patients
were included by cohorts of 3 patients (cohort). Currently, 18 patients have been enrolled
(pat_incl). For each patient, two vectors corresponding to the dose levels of each agent
administered to the patient should be given:
dose_adm1 <- c(1,1,1,1,1,1,2,2,2,3,3,3,3,3,3,2,2,2)
dose_adm2 <- c(1,1,1,2,2,2,1,1,1,1,1,1,1,1,1,2,2,2)
A vector containing the binary toxicity outcome for each patient has to be dened.
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toxicity <- c(0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0)
The full follow-up time for ecacy assessment was set to 7 weeks. As ecacy is assessed
as a time-to-progression, for each patient, the follow-up time (maximum equal to the full
follow-up time) as well as the time-to-progression are required. If no progression is observed
for the patient, then the value should be set to +Inf.
time_prog <- c(1.6,4.2,3.5,5.1,2.4,4.8,2.8,4.4,+Inf,3.9,+Inf,4.6,1.8,+Inf,
0.5, 5.4,2.8,+Inf)
time_follow <- c(rep(7,15), 4.9, 3.1, 1.3)
The example detailed above results in the following call to the function:
next_dose <- CombPlateau_next(ndose_a1=3, ndose_a2=4, tox_max=0.30,
eff_min=0.20, prior_tox_a1, prior_tox_a2, prior_eff_a1, prior_eff_a2,
stage=0, in_startup=FALSE, cohort=3, pat_incl=18, dose_adm1=dose_adm1,
dose_adm2=dose_adm2, toxicity=toxicity, time_full=7, time_prog=time_prog,
time_follow=time_follow)
This code takes two seconds to run. The output reports the number of patients included,
observed toxicities and progressions at each combination according to the entries:
Number of patients:
Agent 1
Agent 2 1 2 3
4 0 0 0
3 0 0 0
2 3 3 0
1 3 3 6
Number of toxicities:
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Agent 1
Agent 2 1 2 3
4 0 0 0
3 0 0 0
2 1 0 0
1 0 0 2
Number of progressions:
Agent 1
Agent 2 1 2 3
4 0 0 0
3 0 0 0
2 3 1 0
1 3 2 4
Then estimated toxicities and ecacies leading to recommendation of combinations are
given:
Toxicity prob:
Agent 1
Agent 2 1 2 3
4 0.21 0.31 0.40
3 0.17 0.25 0.34
2 0.13 0.19 0.26
1 0.08 0.13 0.18
P(toxicity prob > tox_max):
Agent 1
Agent 2 1 2 3
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4 0.35 0.51 0.67
3 0.23 0.39 0.58
2 0.08 0.19 0.40
1 0.01 0.04 0.18
Efficacy prob:
Agent 1
Agent 2 1 2 3
4 0.35 0.51 0.66
3 0.32 0.48 0.63
2 0.24 0.39 0.54
1 0.13 0.26 0.40
P(efficacy prob < eff_min):
Agent 1
Agent 2 1 2 3
4 0.75 0.97 0.99
3 0.72 0.96 0.99
2 0.61 0.95 0.99
1 0.24 0.73 0.93
Prob plateau: Agent 2
4 3 2 1
0.38 0.27 0.19 0.15
Start-up phase ended: YES
NEXT RECOMMENDED COMBINATION: (3,2)
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The next recommended combination is (3; 2). With the current data, the plateau location
for the MTA is estimated at dose level 4 (highest posterior probability), which means that
with the dose involved, the ecacy plateau should not be reached. Other entries are also
recalled:
Number of patients included: 18
Maximum toxicity: 0.3
Minimum efficacy: 0.2
Prior toxicity probabilities for agent 1:
[1] 0.2 0.3 0.4
Prior toxicity probabilities for agent 2:
[1] 0.12 0.20 0.30 0.40
Prior efficacy probabilities for agent 1:
[1] 0.3 0.4 0.5
Prior efficacy probabilities for agent 2:
[1] 0.30 0.40 0.50 0.59
Toxicity threshold: 0.85
Efficacy threshold: 0.1
Toxicity is binary
Efficacy is a time-to-event
Full follow-up time: 7
Minimum waiting time between two dose cohorts is of one toxicity cycle of: 0
4 Conclusions
The dfcomb package implements two methods for phase I clinical trials in oncology for the
combination of two agents depending on the underlying assumptions: either both toxicity
and ecacy increase with the dose of each agent involved (e.g. combination of two cytotoxic
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agents), or the ecacy can plateau with the dose of one agent (e.g. combination of a cytotoxic
agent with a molecularly targeted agent). For each method, the package implements a single
prospective clinical trial or simulation studies. In this package, several exible inputs can
be used, such as: (1) prior information on each agent gathered before the trial, (2) the
cohort size of patients allocated at each combination level as well as the total sample size, (3)
the targeted toxicity, (4) binary or censured data among other possible entries. In the last
decade some innovative methods have been proposed for combination studies. However, the
implementation of such complex approaches is dicult as most commercial software programs
do not provide functions or macros for these approaches. Indeed, many early phase clinical
trial methods are not used in practice as programs or scripts are not available. Our R package
enables statisticians and physicians to implement adaptive model-based dose-nding designs
when two anti-cancer agents are studied.
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